Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.63 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20651369 | 1.00 | SPHK1 (0.63) | SPHK1SPHK2CNR2CYP3A4CYP1A2 | |
| SCHEMBL13896122 | 0.87 | SPHK1 (0.52) | SPHK1SPHK2CNR2CYP3A4CYP1A2 | |
| SCHEMBL15257479 | 0.87 | SPHK1 (0.52) | SPHK1SPHK2CNR2CYP3A4CYP1A2 | |
| SCHEMBL21287632 | 0.85 | SPHK1 (0.66) | SPHK1SPHK2CYP3A4MEN1KMT2A | |
| SCHEMBL13250873 | 0.77 | TRPA1 (0.44) | SPHK1SPHK2CNR2CYP3A4CYP1A2 | |
| SCHEMBL13272155 | 0.77 | TRPA1 (0.44) | SPHK1SPHK2CNR2CYP3A4CYP1A2 | |
| SCHEMBL20905106 | 0.77 | SPHK1 (0.70) | SPHK1SPHK2CYP1A2 | |
| SCHEMBL20596127 | 0.77 | SPHK1 (1.00) | SPHK1SPHK2CYP3A4 | |
| SCHEMBL18194573 | 0.77 | SPHK1 (1.00) | SPHK1SPHK2CYP3A4 | |
| SCHEMBL120911 | 0.77 | SPHK1 (1.00) | SPHK1SPHK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024259-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | ENZO BIOCHEM, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024259-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | ENZO BIOCHEM, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11737992-B2 | Sphingosine kinase Type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11737992-B2 | Sphingosine kinase Type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11723895-B2 | Sphingosine pathway modulating compounds for the treatment of coronavirus infection | ENZO BIOCHEM, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723895-B2 | Sphingosine pathway modulating compounds for the treatment of coronavirus infection | ENZO BIOCHEM, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230158003-A1 | Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection | ENZO BIOCHEM, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158003-A1 | Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection | ENZO BIOCHEM, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210290600-A1 | Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection | ENZO BIOCHEM, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210290567-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION | ENZO BIOCHEM, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-2496225-B1 | SPHINGOSINE TYPE 1 INHIBITORS AND METHODS FOR MAKING AND USING SAME | ENZO THERAPEUTICS INC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10166204-B2 | Sphingosine kinase type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-9974758-B2 | Sphingosine kinase type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974758-B2 | Sphingosine kinase type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160317472-A1 | Sphingosine Kinase Type 1 Inhibitors and Uses Thereof | ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9388121-B2 | Sphingosine kinase type 1 inhibitors | ENZO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20130245321-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS | VIRGINIA COMMONWEALTH UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| US-8314151-B2 | Sphingosine kinase type 1 inhibitors, and processes for using same | ENZO THERAPEUTICS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120237448-A9 | SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME | VIRGINIA COMMONWEALTH UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| US-20100278741-A1 | Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same | ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237448-A9 | SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885CNR2 679/4885 |
| US-20160317472-A1 | Sphingosine Kinase Type 1 Inhibitors and Uses Thereof | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885CNR2 1014/4885 |
| US-11723895-B2 | Sphingosine pathway modulating compounds for the treatment of coronavirus infection | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885CNR2 311/4885 |
| US-20230158003-A1 | Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885CNR2 311/4885 |
| US-20130245321-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885CNR2 524/4885 |
| US-20100278741-A1 | Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885CNR2 546/4885 |
| US-20210290567-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885CNR2 311/4885 |
| US-11737992-B2 | Sphingosine kinase Type 1 inhibitors and uses thereof | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885CNR2 404/4885 |
| US-10166204-B2 | Sphingosine kinase type 1 inhibitors and uses thereof | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885CNR2 1014/4885 |
| US-20210290600-A1 | Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885CNR2 311/4885 |
| US-20240024259-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885CNR2 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.